The only biomarkers approved by regulatory authorities are tumor-based features, such as programmed death ligand 1 (PD-L1) expression on tumor cells, tumor mutational burden (TMB), and DNA repair defects including deficient mismatch repair (dMMR) and high microsatellite instability (MSI-H) [9]. This evidence concerns the gene CD274 and neoplasm.